Key result
The recombinant chimeric protein 6F/PV1N123 elicited neutralizing antibodies against both rotavirus Wa (titer 1:320) and poliovirus type 1 (titer 1:400) in guinea pigs.
A recombinant chimeric protein containing epitopes of poliovirus type 1 and rotavirus VP6 elicited neutralizing antibodies against both viruses in a guinea pig model.
Supports chimeric antigen design in animals; leaves open human immunogenicity and efficacy trials.
To design a vaccine that simultaneously prevents both rotavirus (RV) and poliovirus (PV), a PV type 1 (PV1) chimeric protein using RV VP6 as a vector (VP6F) was constructed, expressed in Escherichia coli expression system and characterized by SDS-PAGE, Western blot, immunofluorescence assay and neutralization test. The results showed that the chimeric protein reacted with anti-VP6F and anti-PV1 antibodies and elicited production of serum antibodies against the chimeric protein in guinea pigs. Antibodies against the chimeric protein neutralized RV Wa and PV1 infection in vitro. The results provided a relevant possibility of developing novel approaches in the rational design of vaccines effective against both RV and PV.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2016) studied Rotavirus and Poliovirus infection (n=28). Recombinant chimeric protein 6F/PV1N123 vs. Vector protein VP6F, PBS (negative control), and reference virus strains was evaluated on Neutralizing antibody titers against rotavirus Wa and poliovirus type 1. The recombinant chimeric protein 6F/PV1N123 elicited neutralizing antibodies against both rotavirus Wa (titer 1:320) and poliovirus type 1 (titer 1:400) in guinea pigs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: